Skip to search formSkip to main contentSkip to account menu

Exenatide versus Insulin Glargine in Patients with Suboptimally Controlled Type 2 Diabetes

This multicenter, 26-week, randomized trial compared the addition of exenatide or insulin glargine to regimens of 551 patients with suboptimally controlled type 2 diabetes, and found both additions led to similar reductions in hemoglobin A1c levels.
View on PubMed (opens in a new tab)

Expression of a Mutant Form of the Ferritin Light Chain Gene Induces Neurodegeneration and Iron Overload in Transgenic Mice

It is reported that the expression in transgenic mice of a human FTL cDNA carrying a thymidine and cytidine insertion at position 498 leads to the formation of nuclear and cytoplasmic ferritin inclusion bodies, which are seen in glia and neurons throughout the CNS as well as in cells of other organ systems.
View on Publisher (opens in a new tab)

Metabolic effects of pioglitazone in combination with insulin in patients with type 2 diabetes mellitus whose disease is not adequately controlled with insulin therapy: results of a six-month,…

View on PubMed (opens in a new tab)

Comparison of effect of pioglitazone with metformin or sulfonylurea (monotherapy and combination therapy) on postload glycemia and composite insulin sensitivity index during an oral glucose tolerance…

Pioglitazone improves postload glycemia and CISI more than metformin or gliclazide when used as monotherapy or in combination therapy in patients with type 2 diabetes.
View on PubMed (opens in a new tab)

Pioglitazone elicits long-term improvements in insulin sensitivity in patients with type 2 diabetes: comparisons with gliclazide-based regimens

The PIO- based regimens resulted in improved insulin sensitivity and more favourable insulin sensitivity-related lipid profiles compared with the GLIC-based regimens and may be important in the management of cardiovascular risk in patients with type 2 diabetes.
View on Springer (opens in a new tab)

Pioglitazone as monotherapy or in combination with sulfonylurea or metformin enhances insulin sensitivity (HOMA-S or QUICKI) in patients with type 2 diabetes

Evaluating the effect of PIO monotherapy and in combination therapy with sulfonylurea (SU) or metformin (MET) on insulin sensitivity as assessed by HOMA-S and QUICKI in a large group of patients found them suitable for use with large study populations.
View on Taylor & Francis (opens in a new tab)

Long‐term effects of pioglitazone and metformin on insulin sensitivity in patients with Type 2 diabetes mellitus

  • M. RodenM. Laakso M. Tan
  • Medicine, Biology
    Diabetic medicine : a journal of the British…
  • 1 August 2005
The changes in insulin sensitivity, as assessed by the Quantitative Insulin Sensitivity Check Index (QUICKI), in patients with T2DM who used metformin or pioglitazone as monotherapy or in combination therapy with sulphonylurea is studied.
View on Wiley (opens in a new tab)

Erratum: Comparison of effect of pioglitazone with metformin or sulfonylurea (monotherapy and combination therapy) on postload glycemia and composite insulin sensitivity index during an oral glucose…

View via Publisher (opens in a new tab)

The use of checksums to ensure data integrity in the healthcare industry

This paper will provide some background on the use of checksums and concentrate on a particular example using lab instrument data, which can be used to verify whether or not a file has been altered.
View via Publisher (opens in a new tab)

Adding New Rows in the ADaM Basic Data Structure: When and How

This HOW uses a Vital Signs example, demonstrating the common BDS dataset need of adding analysis parameters and visits, and will start with a general specification and mock-up to create metadata content that can be used for both detailed specification and within a define document.
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)